Condition: Breast Carcinoma · Sponsor: Institut Curie
Eclectic is a strategy trial; once the class of treatment (endocrine therapy or chemotherapy) has been allocated according to 16α-18F-fluoro-17β-oestradiol (18F-FES) Positron Emission Tomography/Computed Tomography (PET/CT) results and circulating tumor biomarkers, clinicians will decide which treatment to use.
This description comes directly from the study's public registry record.
François-Clément BIDARD, PhD · +33147111515 · francois-clement.bidard@curie.fr
Isabelle TURBIEZ · +33156245630 · drci.promotion@curie.fr
Always discuss trial participation with your own doctor first.
| Centre Hospitalier de la Côte basque | Bayonne, France | Not Yet Recruiting |
| Institut Bergonié | Bordeaux, France | Not Yet Recruiting |
| Polyclinique Bordeaux Nord Aquitaine | Bordeaux, France | Not Yet Recruiting |
| Centre Francois Baclesse | Caen, France | Recruiting |
| Centre Georges Francois Leclerc | Dijon, France | Recruiting |
| Centre Oscar Lambret | Lille, France | Recruiting |
| CHU Limoges | Limoges, France | Not Yet Recruiting |
| Centre Leon Bérard | Lyon, France | Not Yet Recruiting |
| Institut Paoli-Calmettes | Marseille, France | Recruiting |
| Institut du Cancer Montpellier | Montpellier, France | Recruiting |
| Centre Antoine lacassagne | Nice, France | Recruiting |
| Hôpital Universitaire de Nimes | Nîmes, France | Not Yet Recruiting |
+ 9 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06195709